Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen

Elizabeth R. Sharlow, David Close, Tongying Shun, Stephanie Leimgruber, Robyn Reed, Gabriela Mustata, Peter Wipf, Jacob Johnson, Michael O'Neil, Max Grögl, Alan J. Magill, John S. Lazo

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Patients with clinical manifestations of leishmaniasis, including cutaneous leishmaniasis, have limited treatment options, and existing therapies frequently have significant untoward liabilities. Rapid expansion in the diversity of available cutaneous leishmanicidal chemotypes is the initial step in finding alternative efficacious treatments. To this end, we combined a low-stringency Leishmania major promastigote growth inhibition assay with a structural computational filtering algorithm. After a rigorous assay validation process, we interrogated ∼200,000 unique compounds for L. major promastigote growth inhibition. Using iterative computational filtering of the compounds exhibiting >50% inhibition, we identified 553 structural clusters and 640 compound singletons. Secondary confirmation assays yielded 93 compounds with EC50s ≤ 1 μM, with none of the identified chemotypes being structurally similar to known leishmanicidals and most having favorable in silico predicted bioavailability characteristics. The leishmanicidal activity of a representative subset of 15 chemotypes was confirmed in two independent assay formats, and L. major parasite specificity was demonstrated by assaying against a panel of human cell lines. Thirteen chemotypes inhibited the growth of a L. major axenic amastigote-like population. Murine in vivo efficacy studies using one of the new chemotypes document inhibition of footpad lesion development. These results authenticate that low stringency, large-scale compound screening combined with computational structure filtering can rapidly expand the chemotypes targeting in vitro and in vivo Leishmania growth and viability.

Original languageEnglish (US)
Article numbere540
JournalPLoS neglected tropical diseases
Volume3
Issue number11
DOIs
StatePublished - Nov 1 2009

Fingerprint

Leishmania major
Growth
Cutaneous Leishmaniasis
Leishmaniasis
Leishmania
Computer Simulation
Biological Availability
Parasites
Therapeutics
Cell Line
Skin
Population

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Sharlow, Elizabeth R. ; Close, David ; Shun, Tongying ; Leimgruber, Stephanie ; Reed, Robyn ; Mustata, Gabriela ; Wipf, Peter ; Johnson, Jacob ; O'Neil, Michael ; Grögl, Max ; Magill, Alan J. ; Lazo, John S. / Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. In: PLoS neglected tropical diseases. 2009 ; Vol. 3, No. 11.
@article{a045f55f8c894fc2b7da14ee67358070,
title = "Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen",
abstract = "Patients with clinical manifestations of leishmaniasis, including cutaneous leishmaniasis, have limited treatment options, and existing therapies frequently have significant untoward liabilities. Rapid expansion in the diversity of available cutaneous leishmanicidal chemotypes is the initial step in finding alternative efficacious treatments. To this end, we combined a low-stringency Leishmania major promastigote growth inhibition assay with a structural computational filtering algorithm. After a rigorous assay validation process, we interrogated ∼200,000 unique compounds for L. major promastigote growth inhibition. Using iterative computational filtering of the compounds exhibiting >50{\%} inhibition, we identified 553 structural clusters and 640 compound singletons. Secondary confirmation assays yielded 93 compounds with EC50s ≤ 1 μM, with none of the identified chemotypes being structurally similar to known leishmanicidals and most having favorable in silico predicted bioavailability characteristics. The leishmanicidal activity of a representative subset of 15 chemotypes was confirmed in two independent assay formats, and L. major parasite specificity was demonstrated by assaying against a panel of human cell lines. Thirteen chemotypes inhibited the growth of a L. major axenic amastigote-like population. Murine in vivo efficacy studies using one of the new chemotypes document inhibition of footpad lesion development. These results authenticate that low stringency, large-scale compound screening combined with computational structure filtering can rapidly expand the chemotypes targeting in vitro and in vivo Leishmania growth and viability.",
author = "Sharlow, {Elizabeth R.} and David Close and Tongying Shun and Stephanie Leimgruber and Robyn Reed and Gabriela Mustata and Peter Wipf and Jacob Johnson and Michael O'Neil and Max Gr{\"o}gl and Magill, {Alan J.} and Lazo, {John S.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1371/journal.pntd.0000540",
language = "English (US)",
volume = "3",
journal = "PLoS Neglected Tropical Diseases",
issn = "1935-2727",
publisher = "Public Library of Science",
number = "11",

}

Sharlow, ER, Close, D, Shun, T, Leimgruber, S, Reed, R, Mustata, G, Wipf, P, Johnson, J, O'Neil, M, Grögl, M, Magill, AJ & Lazo, JS 2009, 'Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen', PLoS neglected tropical diseases, vol. 3, no. 11, e540. https://doi.org/10.1371/journal.pntd.0000540

Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. / Sharlow, Elizabeth R.; Close, David; Shun, Tongying; Leimgruber, Stephanie; Reed, Robyn; Mustata, Gabriela; Wipf, Peter; Johnson, Jacob; O'Neil, Michael; Grögl, Max; Magill, Alan J.; Lazo, John S.

In: PLoS neglected tropical diseases, Vol. 3, No. 11, e540, 01.11.2009.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen

AU - Sharlow, Elizabeth R.

AU - Close, David

AU - Shun, Tongying

AU - Leimgruber, Stephanie

AU - Reed, Robyn

AU - Mustata, Gabriela

AU - Wipf, Peter

AU - Johnson, Jacob

AU - O'Neil, Michael

AU - Grögl, Max

AU - Magill, Alan J.

AU - Lazo, John S.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Patients with clinical manifestations of leishmaniasis, including cutaneous leishmaniasis, have limited treatment options, and existing therapies frequently have significant untoward liabilities. Rapid expansion in the diversity of available cutaneous leishmanicidal chemotypes is the initial step in finding alternative efficacious treatments. To this end, we combined a low-stringency Leishmania major promastigote growth inhibition assay with a structural computational filtering algorithm. After a rigorous assay validation process, we interrogated ∼200,000 unique compounds for L. major promastigote growth inhibition. Using iterative computational filtering of the compounds exhibiting >50% inhibition, we identified 553 structural clusters and 640 compound singletons. Secondary confirmation assays yielded 93 compounds with EC50s ≤ 1 μM, with none of the identified chemotypes being structurally similar to known leishmanicidals and most having favorable in silico predicted bioavailability characteristics. The leishmanicidal activity of a representative subset of 15 chemotypes was confirmed in two independent assay formats, and L. major parasite specificity was demonstrated by assaying against a panel of human cell lines. Thirteen chemotypes inhibited the growth of a L. major axenic amastigote-like population. Murine in vivo efficacy studies using one of the new chemotypes document inhibition of footpad lesion development. These results authenticate that low stringency, large-scale compound screening combined with computational structure filtering can rapidly expand the chemotypes targeting in vitro and in vivo Leishmania growth and viability.

AB - Patients with clinical manifestations of leishmaniasis, including cutaneous leishmaniasis, have limited treatment options, and existing therapies frequently have significant untoward liabilities. Rapid expansion in the diversity of available cutaneous leishmanicidal chemotypes is the initial step in finding alternative efficacious treatments. To this end, we combined a low-stringency Leishmania major promastigote growth inhibition assay with a structural computational filtering algorithm. After a rigorous assay validation process, we interrogated ∼200,000 unique compounds for L. major promastigote growth inhibition. Using iterative computational filtering of the compounds exhibiting >50% inhibition, we identified 553 structural clusters and 640 compound singletons. Secondary confirmation assays yielded 93 compounds with EC50s ≤ 1 μM, with none of the identified chemotypes being structurally similar to known leishmanicidals and most having favorable in silico predicted bioavailability characteristics. The leishmanicidal activity of a representative subset of 15 chemotypes was confirmed in two independent assay formats, and L. major parasite specificity was demonstrated by assaying against a panel of human cell lines. Thirteen chemotypes inhibited the growth of a L. major axenic amastigote-like population. Murine in vivo efficacy studies using one of the new chemotypes document inhibition of footpad lesion development. These results authenticate that low stringency, large-scale compound screening combined with computational structure filtering can rapidly expand the chemotypes targeting in vitro and in vivo Leishmania growth and viability.

UR - http://www.scopus.com/inward/record.url?scp=73449120692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449120692&partnerID=8YFLogxK

U2 - 10.1371/journal.pntd.0000540

DO - 10.1371/journal.pntd.0000540

M3 - Article

C2 - 19888337

AN - SCOPUS:73449120692

VL - 3

JO - PLoS Neglected Tropical Diseases

JF - PLoS Neglected Tropical Diseases

SN - 1935-2727

IS - 11

M1 - e540

ER -